NCT02089126Unknown3 期
A Multicenter, Randomized, Placebo-controlled, Parallel Group, Double-blind, Phase III Trial to Evaluate the Efficacy and Safety of Gemigliptin 50mg qd Added to Ongoing Glimepiride as Fix-dose Combination in Patients With Type 2 Diabetes Inadequately Controlled on Glimepiride Alone
LG Life Sciences1 个研究点 分布在 1 个国家目标入组 230 人开始时间: 2014年6月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 发起方
- 入组人数
- 230
- 试验地点
- 1
- 主要终点
- HbA1c Changes
研究概览
简要总结
The study objective is to demonstrate the superiority and safety of the combination therapy (as a fix-dose combination) with Gemigliptin and Glimepiride, compared to the Glimepiride monotherapy in patients with type 2 diabetes.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 19 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with type 2 diabetes
- •Adults who are at least 19 years old
- •Patients who have taken Glimepiride at a stable dose (≥4mg/day) for 8 weeks or more before Visit 1 (screening) as monotherapy or Patients who have taken Glimepiride at a stable dose (≥4mg/day) and Metformin for 8 weeks or more before Visit 1 (screening) as combination therapy
- •Patients who satisfy the following HbA1c (%) criteria: 7 ≤ HbA1c ≤ 11
- •Patients who have been provided an explanation about the objective, method, effects, etc. of the clinical trial and whose informed consent form has been signed by himself/herself or his/her representative
- •Patients who fall under one of the following 3 cases
- •Patients who are surgically sterile
- •Post-menopausal females who are above 45 years of age and 2 years after the last menstruation
- •Fertile premenopausal female patients or male patients without having a surgical sterilization, who have agreed to use at least two contraception methods (one of the barrier methods must be included) for up to 14 days after the administration of the last investigational product to avoid pregnancy.
排除标准
- •Patients with type 1 diabetes, diabetic ketoacidosis, diabetic coma and pre-coma
- •Patients with gestational diabetes or secondary diabetes
- •Patients with NYHA Class III, IV congestive heart failure or arrhythmias requiring treatment
- •Patients with thyroid gland dysfunction and TSH that is out of normal range
- •Patients with pituitary insufficiency or adrenal insufficiency
- •Patients with hereditary problems, such as galactose intolerance, Lapp lactose deficiency or glucose-galactose malabsorption
- •Female patients who are pregnant or breastfeeding
- •Patients whose BMI exceeds 40 kg/m2
- •Patients whose creatinine clearance is below 30mL/min/1.73m2
- •Patients whose bilirubin level exceeds 1.5 times the upper limit of the normal range and whose ALT/AST level exceeds 2.5 times the upper limit of the normal range
- •Patients who are continuously taking the following drugs for 2 weeks or more at Visit 1 (screening), or need to take them continuously and repeatedly
- •cyclosporin, sirolimus, tacrolimus, nicotinic acid (≥1500mg/day), isotretinoin
- •Strong CYP3A4 inducers: rifampicin (rifampin), phenytoin, carbamazepine, rifabutin, phenobarbital
- •warfarin, dicoumarin, digoxin
- •systemic glucocorticoids
- •Patients who have taken anti-obesity drugs or had a surgery related to obesity within 12 weeks before Visit 1 (screening)
- •Patients who have received insulin and GLP-1 analogue treatment within 8 weeks prior to Visit 1 (screening)
- •Patients who have received a treatment due to malignant tumor within 5years before Visit 1 (screening) However, patients whose basal cell or squamous cell skin cancer or in situ cervical cancer has been treated can be enrolled.
- •Patients with a history of myocardial infarction, unstable angina and coronary artery bypass surgery within 6 months prior to Visit 1 (screening)
- •Patients with a history of alcohol or drug addiction within 1 year prior to Visit 1 (screening)
- •Patients who have a medical history of hypersensitivity to the same class as Gemigliptin or dipeptidyl peptidase 4 (DPP 4) inhibitor drugs
- •Patients with a history of hypersensitivity to the drugs belonging to the same class as Glimepiride or sulfonylureas and sulfonamide
- •Patients who have participated in another clinical trial within 3 months prior to Visit 1 (screening)
- •Patients deemed unsuitable for this trial based on the judgment of the investigator
研究组 & 干预措施
Gemigliptin/Glimepiride combination
Experimental
Gemigliptin 50mg qd added to ongoing Glimepiride as fix-dose combination. The subjects will take a total of 2 tablets, Gemigliptin/Glimepiride combination & Placebo for Glimepiride.
干预措施: Gemigliptin/Glimepiride combination (Drug)
结局指标
主要结局
HbA1c Changes
时间窗: Week 0, Week 24
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Atacicept in Combination With Rituximab in Subjects With Rheumatoid Arthritis (August III)Rheumatoid ArthritisNCT00664521Merck KGaA, Darmstadt, Germany27
已完成
2 期
Study of Safety, Tolerability, and Efficacy of a Combination Treatment of LJN452 and CVC in Adult Patients With NASH and Liver FibrosisNon-alcoholic Steatohepatitis (NASH)NCT03517540Novartis Pharmaceuticals193
已完成
4 期
Utilization of Narrow Band Ultraviolet B (UVB) Light Therapy and Etanercept for the Treatment of PsoriasisPsoriasisNCT00110981Amgen86
招募中
3 期
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 MutationMetastatic Breast CancerNCT05696626LeonaBio600
尚未招募
3 期
Evaluating the Efficacy and Safety of Cleanser, Serum, and Sunscreen Products for Facial Redness.RednessNCT05961579Goldman, Butterwick, Fitzpatrick and Groff20